Editorial Podcasts

Jenny Ahlstrom, founder of the HealthTree Foundation, discusses their community for AML and myeloma patients, how they help their patients navigate clinical trials, how their portal seamlessly gets patients records to researchers, and how industry can utilize their resources and engage with patients.

Dr. Lise Lund Kjems, Chief Medical Officer at Cyclo Therapeutics, talks about Cyclo’s investigational therapy for Niemann-Pick Disease Type C and gives insight into rare disease drug development, with an emphasis on ensuring trial design includes holistic and specific patient concerns.

Bob Chaplinsky, Director Corporate Quality Compliance at UCB, discusses the trajectory of quality management systems in pharma, the importance of change management when implementing new systems, and staying on top of compliance and regulatory changes on a global scale.

Mary Costello, Head of Site and Investigator Network at Medable, and Pat Larrabee, CEO of Rochester Clinical Research, discuss their extensive careers in the clinical trials industry, as well as talk about their article in our October issue, “Why Siteless Trials Won’t Work.”

Jaydev Thakkar, COO of Biofourmis, talks about decentralized trials, clinical research as a care option, digital therapeutics, and what Biofourmis is working on.

Raj Indupuri, CEO of eClinical Solutions, talks about the build vs. buy pendulum faced by CROs, the pros and cons of each model, and more.

Scott Gray, founder and CEO Clincierge, discusses the biggest changes in trial operations, patient centricity, and shares a few stories about obstacles overcome during the coronavirus pandemic.

Brad Power, Founder of CancerHacker Lab, speaks about his innovative crowdsourcing approach to help cancer patients, his own battle with lymphoma, and the unique challenges brought to the table by clinical trials in oncology.

Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.

Mike Rea, CEO and Founder of IDEA Pharma, speaks about how his newly launched sister company—Protodigm—takes lessons learned from IDEA, combined with ideas borrowed from engineering and tech development, to form a new concept in pharma and biotech to innovate drug development with minimized risk and without bias.

Dr. Peter Schueler, Senior VP Drug Development Services, Neurosciences at ICON, talks about topics discussed in a timely new book he edited titled Innovation in Clinical Trial Methodologies.

John Reites, CEO of THREAD Research, discusses how his organization is adapting to decentralized trials and efforts they're taking to increase patient recruitment.

Dr. Theodore Leng, MD, Medical Advisor to Verana Health and Director of Clinical and Translational Research at the Byers Eye Institute at Stanford, Stanford University Medical School, talks about a recent study he led and presented in early May at the Association for Research in Vision and Ophthalmology Meeting.

Courtney Granville, Global Associate Director, Research and Scientific Programs at DIA, talks about the options decentralized trials provide, the options that DIA is offering its members to learn in a hybrid environment, and the options healthcare and research should provide for patients now.